COLL (59) AVBP (29) ARDX (24) ANNX (30) ⌘ Pro Terminal →

Helus Pharma Inc. (HELP) — RQD Stock Rating Cockpit

$10.60 -1.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.56

Helus Pharma Inc. (HELP) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $782.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HELP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Helus Pharma Inc. (NASDAQ: HELP) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $10.60 (-1.07% 1D, market cap $782.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HELP ranks #244 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HELP compare to COLL and AVBP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and AVBP (ArriVent BioPharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HELP?

▼

For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #244 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.56 (-0.38%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HELP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY HELP SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0.5% FCF Margin ($21.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$11.03-3.1% Next Q

Q2 (-2Q)

Grade C$10.69-3.1% Next Q

Q3 (-1Q)

Grade C$10.36+2.3% Next Q

Current

Grade D+$10.60-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HELP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HELP currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.92) and Max Pain ($11.13) forces dealer call-delta covering toward $15.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HELP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HELP Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE60% OF RANGE

L: $4$10.60H: $15

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on HELP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

18/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like HELP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HELP)

✓Walkthrough of HELP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HELP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +100.38%🛡️ HOLDING TREND SUPPORT

2026-11-02O $10.91H $10.91L $10.60C $10.60VOL 790.4K

RES: $11.99SUP: $9.56SMA50: $11.92SMA200: $7.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HELP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HELP Butterfly Map → + Track HELP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HELP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HELP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HELP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HELP)

Health Care Rank #244 of 1016 ⚔️ COLL vs HELP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HELP vs. COLL, AVBP, ARDX, ANNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Helus Pharma Inc. (HELP) ranks #244 by composite RQD confidence (54/100, grade D+) and #388 by equity capitalization ($782.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with HELP at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HELP ACTIVE Helus Pharma Inc.	D+	54/100	—	—	—	-1.07%	$782.5M	Benchmark Subject
COLL Collegium Pharmaceutical Inc.	C-	59/100	12.4x	59.3%	85.0%	-0.96%	$782.3M	/coll-vs-help →
AVBP ArriVent BioPharma Inc.	E	29/100	—	—	-35.0%	-6.77%	$786.5M	/avbp-vs-help →
ARDX Ardelyx Inc.	E	24/100	—	90.3%	-32.7%	-2.26%	$772.5M	/ardx-vs-help →
ANNX Annexon Inc.	E	30/100	—	—	-35.0%	+1.00%	$760.2M	/annx-vs-help →

2. HELP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Helus Pharma Inc. (HELP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $782.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HELP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HELP compare to COLL and AVBP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HELP?

Where is HELP trading relative to its 50-day, 200-day, and 52-week technical levels?

HELP last traded at $10.60 (-1.07% on volume of 1,146,361 shares), positioning the stock -11.07% below its 50-day simple moving average ($11.92) and +37.13% above its 200-day simple moving average ($7.73). Across its 52-week range of $3.76 to $15.15, HELP sits at the 60.1% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.28 to $11.92).

HELP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HELP stock right now?

Helus Pharma Inc. (HELP) currently earns a Roarable Rating of D+ (Sell — SELL) with 54/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is HELP's 12-month price target and RQD AI Jury consensus?

HELP's 12-month base price target is $10.41 (range $8.12 to $15.91), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HELP RQD Cockpit HELP 12M Forecast HELP Earnings & Move HELP Dividends & DRIP HELP Insiders & 13F HELP Whale Options HELP Profit Sankey HELP News & Why

ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HELP — Helus Pharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:14:49Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HELP scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The Fundamental Cash Engine pillar scores 12 of 20, reflecting an ROIC of 0% and an FCF yield of 0%; for a prospective investor, this means the rating does not credit the company with a current cash-generating engine. The Whale 13F Flow pillar scores 9 of 20 for institutional accumulation and options positioning, indicating limited support from institutional flow in the rating's view. The Insider Conviction pillar scores 9 of 20 for SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 11 of 20, with a beta of 1.0 and a sector sensitivity that the source does not further decompose. The Forensic Balance Sheet pillar scores 13 of 20, the strongest of the five, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Taken together, the rating frames the stock's upside as dependent on future catalysts rather than current cash generation, while its balance-sheet metrics are the most supportive element. Valuation tradeoffs cannot be fully assessed because P/E, forward P/E, and EV/EBITDA are not available in source data. This is an analytical framing, not personalized financial advice.

Business

Helus Pharma Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile section. The company's product offerings, customer base, and revenue model are not described in the source data. The source references a clinical program, including an HLP003 Phase 3 readout, per the recent news section, but the source does not describe how the company monetizes any product.

Recent Catalysts & News Wire Analysis

Per the recent news section, the items are:

A Yahoo Finance Singapore report on market action, institutional positioning, and fundamental catalysts (YELLOW, MARKET WIRE).
A Seeking Alpha report titled as a buy ahead of the HLP003 Phase 3 readout (YELLOW, MARKET WIRE).
A company release on clinical program advancements at an investor presentation held October 21, 2026 (YELLOW, MARKET WIRE).
An Investing.com report that H.C. Wainwright reiterated a buy rating (YELLOW, MARKET WIRE).
A kalkine.ca report describing a 7.29% stock drop as volatility builds ahead of the Phase 3 APPROACH readout for HLP003 (RED, RISK WATCH).
A Yahoo Finance report on the October 21, 2026 investor presentation (YELLOW, MARKET WIRE).

The RED-flagged item is the only risk-watch signal. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlation links cannot be identified from source data. The key 2nd-order item a prospective investor should monitor is the HLP003 Phase 3 readout referenced in the news section, since the news frames near-term price volatility around that event, but the source does not establish any supply-chain dependency on it.

Open Questions

What are the company's reported revenues, operating income, and net income across recent periods, given that the financials section is empty?
What product or product candidate generates revenue, and what is the commercial status of HLP003?
What are the P/E, forward P/E, and EV/EBITDA multiples, given that these are unavailable?
What is the outcome and timing of the HLP003 Phase 3 readout referenced in the news?
What are the cash, debt, and free-cash-flow figures underlying the Piotroski F-Score and Altman Z-Score cited in the rating?

HELP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Helus Pharma Inc. (HELP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HELP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 6h ago

Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history

Yahoo Finance Singapore report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 9h ago

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP)

Seeking Alpha report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Helus Pharma • 12h ago

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 - Wed, 10/21/2026 - 16:10

Helus Pharma report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 15h ago

H.C. Wainwright reiterates Helus Pharma stock rating at buy

Investing.com report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 18h ago

Helus Pharma Stock Drops 7.29% as Volatility Builds Ahead of Pivotal Phase 3 APPROACH Readout for HLP003 (CN:HELP)

kalkine.ca report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

Helus Pharma to Host Investor Presentation on October 21, 2026

Yahoo Finance report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

Helus Pharma Stock Faces Renewed Pressure as Bearish Momentum Raises Correction Risk — Healthcare

kalkine.ca report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health - Slideshow (NASDAQ:HELP) 2026-10-23

Seeking Alpha report covering Helus Pharma Inc. (HELP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HELP Bull vs. Bear Conversation Board — What's Your Call at $10.60?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HELP 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $11.57 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HELP (D+ • RQD 54/100) a Buy at $10.71?

Welcome to the HELP (Helus Pharma Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.03 (-25.0%)

Spot @ $10.71

Pump the brakes on HELP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HELP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Helus Pharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.71 (+28.0%)

Spot @ $10.71

HELP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HELP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.71 (52-wk range $3.76 - $15.15), any beat on forward guidance forces shorts and underweight funds to chase.